Author

Hélène Guillemin‐Paveau

Observed names: H. GUILLEMIN-PAVEAU, H. Guillemin-Paveau, Helene Guillemin-Paveau, Helene Guillemin‐Paveau

Institution: Sanofi (France)

Observed institution: Sanofi (France)

OpenAlex ID: A5004192092

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study

2020 · Kazutaka Sunami, Kenshi Suzuki, et al. · Cancer Science · 19

First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)

2016 · A. Gazzah, N. Stjepanovic, et al. · European Journal of Cancer · 10

1046P Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results

2023 · J. Yong Hong, B-Y. Ryoo, et al. · Annals of Oncology · 8

Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGFβ inhibitor, as monotherapy or in combination with cemiplimab in a phase 1/1b study.

2021 · Stephen K. Williamson, F. Stephen Hodi, et al. · Journal of Clinical Oncology · 6

Initial safety and efficacy results from a first-in-human, phase 1/2 study of SAR445877, an anti-PD-1/IL-15 fusion protein, for patients with advanced solid tumors.

2025 · Aung Naing, Khaldoun Almhanna, et al. · Journal of Clinical Oncology · 3

9O Phase I/II, open-label, first-in-human study of the anti-GPC3 T cell engager SAR444200 in patients with advanced solid tumors: Updated safety and pharmacokinetic analysis

2025 · K. Almhanna, J.Y. Hong, et al. · ESMO Open · 3

1074TiP A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors

2023 · M. Gutierrez, E. Garralda, et al. · Annals of Oncology · 3

An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma

2024 · Prashant Kapoor, Nitya Nathwani, et al. · European Journal Of Haematology · 2

779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors

2023 · Martin Gutierrez, Elena Garralda, et al. · Regular and Young Investigator Award Abstracts · 2

Phase 1/2, open-label, first-in-human study of the anti-GPC3 T-cell engager SAR444200 in patients with advanced solid tumors: Updated efficacy and biomarker analysis.

2025 · Ecaterina Elena Dumbrava, Anthony El-Khoueiry, et al. · Journal of Clinical Oncology · 1

782-I Phase I dose escalation of SAR445710, a PDL1-IL15 targeted cytokine in metastatic and/or advanced solid tumors

2023 · Jason Luke, Anthony J Olszanski, et al. · 1

Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors.

2024 · Maxime Chenard-Poirier, Khaldoun Almhanna, et al. · Journal of Clinical Oncology

Works count: 12

Citation count: 58

H-index: 4

I10-index: 2